140 related articles for article (PubMed ID: 1370707)
1. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
Debyser Z; Pauwels R; Andries K; Desmyter J; Engelborghs Y; Janssen PA; De Clercq E
Mol Pharmacol; 1992 Jan; 41(1):203-8. PubMed ID: 1370707
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
[TBL] [Abstract][Full Text] [Related]
3. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
5. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.
Debyser Z; Pauwels R; Andries K; Desmyter J; Kukla M; Janssen PA; De Clercq E
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1451-5. PubMed ID: 1705038
[TBL] [Abstract][Full Text] [Related]
6. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase.
Debyser Z; Pauwels R; Baba M; Desmyter J; De Clercq E
Mol Pharmacol; 1992 May; 41(5):963-8. PubMed ID: 1375320
[TBL] [Abstract][Full Text] [Related]
7. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
Mellors JW; Dutschman GE; Im GJ; Tramontano E; Winkler SR; Cheng YC
Mol Pharmacol; 1992 Mar; 41(3):446-51. PubMed ID: 1372083
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
Pauwels R; Andries K; Desmyter J; Schols D; Kukla MJ; Breslin HJ; Raeymaeckers A; Van Gelder J; Woestenborghs R; Heykants J
Nature; 1990 Feb; 343(6257):470-4. PubMed ID: 1689015
[TBL] [Abstract][Full Text] [Related]
11. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer.
Harris D; Lee R; Misra HS; Pandey PK; Pandey VN
Biochemistry; 1998 Apr; 37(17):5903-8. PubMed ID: 9558323
[TBL] [Abstract][Full Text] [Related]
12. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
[TBL] [Abstract][Full Text] [Related]
13. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
Pauwels R; Andries K; Debyser Z; Kukla MJ; Schols D; Breslin HJ; Woestenborghs R; Desmyter J; Janssen MA; De Clercq E
Antimicrob Agents Chemother; 1994 Dec; 38(12):2863-70. PubMed ID: 7535037
[TBL] [Abstract][Full Text] [Related]
14. Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, R82150.
Frank KB; Noll GJ; Connell EV; Sim IS
J Biol Chem; 1991 Aug; 266(22):14232-6. PubMed ID: 1713579
[TBL] [Abstract][Full Text] [Related]
15. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
Taylor PB; Culp JS; Debouck C; Johnson RK; Patil AD; Woolf DJ; Brooks I; Hertzberg RP
J Biol Chem; 1994 Mar; 269(9):6325-31. PubMed ID: 7509800
[TBL] [Abstract][Full Text] [Related]
16. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
Boyer PL; Ding J; Arnold E; Hughes SH
Antimicrob Agents Chemother; 1994 Sep; 38(9):1909-14. PubMed ID: 7529011
[TBL] [Abstract][Full Text] [Related]
17. Buried surface analysis of HIV-1 reverse transcriptase p66/p51 heterodimer and its interaction with dsDNA template/primer.
Ding J; Jacobo-Molina A; Tantillo C; Lu X; Nanni RG; Arnold E
J Mol Recognit; 1994 Jun; 7(2):157-61. PubMed ID: 7530020
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct.
Chavan SJ; Bornmann WG; Flexner C; Prochaska HJ
Arch Biochem Biophys; 1995 Dec; 324(1):143-52. PubMed ID: 7503549
[TBL] [Abstract][Full Text] [Related]
19. Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
Shao X; Rytting AS; Ekstrand DH; Vrang L; Källander CF; Gronowitz JS
Antivir Chem Chemother; 1998 Mar; 9(2):167-76. PubMed ID: 9875388
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
